Your browser doesn't support javascript.
loading
Immunotherapy in anaplastic thyroid cancer: Case series.
Shih, Shyang-Rong; Chen, Kuan-Hua; Lin, Kuan-Yu; Yang, Pan-Chyr; Chen, Kuen-Yuan; Wang, Chun-Wei; Chen, Chun-Nan; Lin, Chih-Feng; Lin, Chia-Chi.
Afiliação
  • Shih SR; National Taiwan University College of Medicine, Taipei, Taiwan; Division of Endocrinology & Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Center of Anti-Aging and Health Consultation, National Taiwan University Hospital, Taipei, Taiwan.
  • Chen KH; Division of Endocrinology and Metabolism, E-Da Hospital, Kaohsiung, Taiwan.
  • Lin KY; Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Douliou City, Taiwan.
  • Yang PC; National Taiwan University College of Medicine, Taipei, Taiwan; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Chen KY; Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
  • Wang CW; Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Chen CN; Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.
  • Lin CF; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: cclin1@ntu.edu.tw.
J Formos Med Assoc ; 121(6): 1167-1173, 2022 Jun.
Article em En | MEDLINE | ID: mdl-35031200
Unresectable anaplastic thyroid cancer (ATC) has a poor prognosis. Chemotherapy and radiotherapy have limited effects on it. Here, we present four cases who underwent immunotherapy for ATC. The patients were aged between 58 and 70 years. Two male patients with pulmonary metastases received pembrolizumab and lenvatinib. However, they died of septic shock and respiratory failure in 2.7 and 1 months, respectively, after the initiation of combination therapy. Another male patient with stage IVB disease was treated with spartalizumab. The tumor remained stable after surgical debulking but slightly progressed after 23 months. He survived for 45.5 months after spartalizumab initiation. A female patient with BRAF-mutant ATC and lung metastases was treated with a combination of pembrolizumab and lenvatinib, which was complicated with grade 4 transaminitis. The patient subsequently received dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) treatment, which was continued for 10.2 months with a best response of partial remission. She died 18 months after the initial diagnosis (11.4 months after treatment with dabrafenib and trametinib). In conclusion, the treatment responses of immunotherapy, either alone or in combination with other therapies, were highly variable in patients with ATC and should be carefully monitored along with the side effects.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Carcinoma Anaplásico da Tireoide Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Formos Med Assoc Assunto da revista: MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Taiwan

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Carcinoma Anaplásico da Tireoide Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Formos Med Assoc Assunto da revista: MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Taiwan